Photo of Laura Spring,  MD

Laura Spring, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-6500
Fax: (617) 724-1079

Laura Spring, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending Physician, Medical Oncology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Spring is a clinical/translational investigator and breast medical oncologist at the Massachusetts General Hospital Cancer Center and Harvard Medical School. The primary focus of her research is to develop novel therapeutic and biomarker strategies to improve the care of breast cancer patients. She is particularly interested in blood-based monitoring of localized breast cancer and the use of targeted therapies in the neoadjuvant setting. Dr. Spring is the recipient of a Young Investigator Award from the ASCO Conquer Cancer Foundation for her work exploring circulating tumor cell (CTC) monitoring in the neoadjuvant setting in breast cancer. She is involved with the design and conduct of several breast cancer clinical trials for localized and metastatic breast cancer.

Publications

Powered by Harvard Catalyst
  • Spring LM, Marshall MR, Warner ET. Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014. Cancer 2016; 123:401-409. PubMed
  • Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant 2016; 23:113-118. PubMed
  • Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. Oncologist 2016. PubMed
  • Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2016. PubMed
  • Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med 2016; 21:65-74. PubMed
  • Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant 2015; 21:509-16. PubMed
  • Spring L, Robillard D, Gehlbach L, Simas TA. Impact of pass/fail grading on medical students' well-being and academic outcomes. Med Educ 2011; 45:867-77. PubMed